



Suggested Formula	Diltiazem Hydrochloride 120 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 004 532
-------------------	---	-----	-----------

IMPORTANT: This formula is for a **slow release** capsule. Please note that the rate of drug release may not be identical to the release rates of commercial formulations labeled as sustained-release, sustained action, prolonged-action, controlled-release, extended-release, timed-release, targeted release, long-acting, modified-release, etc. As such, this preparation should be prescribed and monitored under the close supervision of the prescribing physician.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Diltiazem Hydrochloride, USP	12.000	g				
Hypromellose (4000 CPS) Methocel E4M, USP	TBD					
Cellulose (microcrystalline), NF	TBD					
Sodium Chloride, USP	As required					

SPECIAL PREPARATORY CONSIDERATIONS

<u>Ingredient-Specific Information</u>	
<i>Light sensitive</i> (protect from light whenever possible):	<i>Diltiazem Hydrochloride</i>
<i>Hygroscopic</i> (protect from moisture whenever possible):	<i>Hypromellose (4000 CPS) Methocel E4M, Cellulose (microcrystalline)</i>
<u>Suggested Preparatory Guidelines</u>	
<input checked="" type="checkbox"/> Non-Sterile Preparation	<input type="checkbox"/> Sterile Preparation
<u>Processing Error / Testing Considerations:</u>	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
<u>Special Instruction:</u>	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Diltiazem Hydrochloride 120 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 004 532
-------------------	---	-----	-----------


SUGGESTED PREPARATION (for 100 Size #1 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : ____	Processing Error	Qty. to measure
Diltiazem Hydrochloride, USP §	12.000	g			
Hypromellose (4000 CPS) Methocel E4M, USP §	TBD				
Cellulose (microcrystalline), NF §	TBD				
Sodium Chloride, USP	As required				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.





Suggested Formula	Diltiazem Hydrochloride 120 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 004 532
-------------------	---	-----	-----------

Preparatory Instruction


1.	<p><u>Excipient requirements for 100 x size #1 capsules</u></p> <p>A. Calculate the amount of Cellulose (microcrystalline) and Hypromellose (4000 CPS) Methocel E4M required for the batch. Refer to attached appendix for details.</p>
2.	<p><u>Powder preparation:</u></p> <p>A. Triturate the Diltiazem Hydrochloride to form a fine, homogeneous powder.</p> <p>B. <u>By geometric addition</u>, combine and mix the following ingredients together to form a homogeneous powder blend:</p> <ul style="list-style-type: none">-Fine, homogeneous powder (Step 2A)-Cellulose (microcrystalline) (Quantity determined in appendix (J))-Hypromellose (4000 CPS) Methocel E4M (Quantity determined in appendix (L)) <p><u>End result:</u> Homogeneous powder blend.</p>
3.	<p><u>Product transfer:</u></p> <p>Fill each of 100 Size #1 capsules with the mixture (Step 2B). Close each capsule tightly.</p> <p>Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.</p>
4.	<p><u>Validation technique (average capsule weight):</u></p> <p>The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (D) + (H) + 0.120 g together.</p>
5.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging Requirements”).</p>



Suggested Formula	Diltiazem Hydrochloride 120 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 004 532
-------------------	---	-----	-----------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	6 months, as per USP.	Packaging Requirements	Tightly closed, light-resistant vial.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Keep in a dry place
	2	Keep out of reach of children.	7	Protect from light.
	3	Keep at room temperature (20°C – 23°C).	8	Cap tightly after use.
	4	May impair mental and/or physical ability. Use care when operating a car or machinery.	9	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	5	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			





Suggested Formula	Diltiazem Hydrochloride 120 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 004 532
-------------------	---	-----	-----------

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 127.
2.	Sandoz Diltiazem T. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2010</i> . 2129.
3.	Hypromellose. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 326.
4.	Cellulose (microcrystalline). In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 129.
5.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 637.
6.	Diltiazem Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1265.
7.	Diltiazem (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #3202.
8.	Diltiazem Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 193.
9.	Diltiazem Hydrochloride (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2159.
10.	Diltiazem. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 731.
11.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Appendix	Calculating the quantity of excipient required for the batch		
----------	--	--	--

Procedure																							
1.	<p><u>Capsule filling:</u></p> <p>a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight.</p> <p>Also, triturate the ingredient powder first if required in formulation.</p> <p>Plug each amount into Step 2, column B.</p>																						
2.	<p><u>Volume Percent Occupied:</u></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; width: 35%;"><u>Ingredients</u></th> <th style="text-align: center; width: 20%;">Column A Quantity Required per capsule</th> <th style="text-align: center; width: 20%;">Column B Average capsule fill weight</th> <th style="text-align: center; width: 25%;">Column C A/B x 100 equals percent filled</th> </tr> </thead> <tbody> <tr> <td>a. Diltiazem Hydrochloride</td> <td style="text-align: center;">0.120 g</td> <td style="text-align: center;">_____ g</td> <td style="text-align: center;">_____ %</td> </tr> <tr> <td>b. Hypromellose (4000 CPS) Methocel</td> <td style="text-align: center;">_____ g (D) (0.40 x column B)</td> <td style="text-align: center;">_____ g</td> <td style="text-align: center;">40%</td> </tr> <tr> <td>c. Cellulose (microcrystalline)</td> <td></td> <td style="text-align: center;">_____ g</td> <td></td> </tr> <tr> <td>d. Total (add column C together)</td> <td></td> <td></td> <td style="text-align: center;">_____ % (E)</td> </tr> </tbody> </table>			<u>Ingredients</u>	Column A Quantity Required per capsule	Column B Average capsule fill weight	Column C A/B x 100 equals percent filled	a. Diltiazem Hydrochloride	0.120 g	_____ g	_____ %	b. Hypromellose (4000 CPS) Methocel	_____ g (D) (0.40 x column B)	_____ g	40%	c. Cellulose (microcrystalline)		_____ g		d. Total (add column C together)			_____ % (E)
<u>Ingredients</u>	Column A Quantity Required per capsule	Column B Average capsule fill weight	Column C A/B x 100 equals percent filled																				
a. Diltiazem Hydrochloride	0.120 g	_____ g	_____ %																				
b. Hypromellose (4000 CPS) Methocel	_____ g (D) (0.40 x column B)	_____ g	40%																				
c. Cellulose (microcrystalline)		_____ g																					
d. Total (add column C together)			_____ % (E)																				
3.	<p><u>Calculate the quantity of Cellulose and Hypromellose required for the batch:</u></p> <p>a. Percent of Cellulose (microcrystalline) required = 100% – E _____ % (F)</p> <p>b. Average capsule fill weight of Cellulose (microcrystalline) (from column B, Step 2c): _____ g (G)</p> <p>c. Quantity of Cellulose (microcrystalline) required per capsule = [(F) ÷ 100 × (G)] _____ g (H)</p> <p>d. Total Quantity of Cellulose (microcrystalline) required for the batch = 100 capsules × (H) _____ g (I)</p> <p>e. Total quantity of Cellulose (microcrystalline) <i>plus</i> processing error = (I) x 1.05-1.09 _____ g (J)</p> <p>f. Total quantity of Hypromellose (4000 CPS) Methocel required for the batch = 100 capsules × (D) _____ g (K)</p> <p>g. Total quantity of Hypromellose (4000 CPS) Methocel <i>plus</i> processing error = (K) x 1.05-1.09 _____ g (L)</p>																						

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.